Louisiana State University Health Sciences Center - Shreveport, Louisiana State University Health Sciences Center - Shreveport, LA
Overview
Mission
Clinical Trials
Members
Course Info
Research
Core Facilities
Contact Us

Key Members

J. Michael Mathis, Ph.D.
Director
Dept. of Cellular Biology and Anatomy


B. Jill Williams, Ph.D.
Associate Director
Dept. of Urology


Arrigo De Benedetti, Ph.D.
Dept. of Biochemistry


Ronald Klein, Ph.D.
Dept. of Pharmacology


Cherie-Ann Nathan, M.D.
Dept. of Otolaryngology


Kate Ryman, Ph.D.
Dept. of Microbiology and Immunology


Francesco Turturro, M.D.
Dept. of Medicine


Wei-Ming Duan, M.D., Ph.D.Dept. of Cellular Biology and Anatomy

Benjamin Li, M.D.

Dept. of Surgery


Qian-Jin Zhang, Ph.D.
Dept. of Cellular Biology & Anatomy

Key Member

Cherie-Ann O. Nathan, M.D.
Professor, Vice-Chairman and Director of Head and Neck Surgical Oncology and Cancer Research

See the Curriculum Vitae
Nathan Lab

     The translation initiation factor eIF4E is overexpressed in a variety of solid tumors and in particular in all HNSCC (Nathan, Oncogne 1997). The biologic importance of eIF4E in HNSCC is underscored by the finding that eIF4E overexpression in surgical margins increases the risk of recurrence by 6.5 fold compared to patients with eIF4E negative margins and is an independent risk factor for recurrence (Nathan JCO, 1999). This was compared to p53 overexpression in the margins and found to be a more sensitive marker for recurrence (Nathan, Cancer Res 2000). When eIF4E, the protein translation factor, is overexpressed in HNSCC it increases the translation of weak mRNAs two of which have been found to be potent angiogenic factors b-FGF and VEGF (Nathan, Oncogene 1997). In an earlier study an episomal vector containing antisense RNA to eIF4E reduced the level of eIF4E in a HNSCC cell line and suppressed both the tumorigenic and angiogenic properties of the cells as demonstrated by loss of capacity to grow in soft agar, reduced expression of angiogenic factors and loss of tumorigenicity in nude mice (DeFatta, Laryngosopce 2000). We intend to decrease the recurrence rate in this group of patients with eIF4E positive margins with a eIF4E antisense adenovirus vector thus decreasing the potential conversion of these occult cells into the malignant phenotype.

Goals

1. To establish eIF4E antisense adenoviral vectors.
2. To demonstrate that this vector suppresses the growth of established tumors of the head and neck in cell culture and in animal models.
3. To then develop a microscopic residual model which mimics the postsurgical environment of head and neck cancer patients.

     At the clinical level, the Otolaryngology /Head and Neck Surgery Dept. at Louisiana State University Health Science Center, Shreveport with the Feist Weiller Cancer Center is enrolling patients with squamous cell carcinoma of the head and neck (SCCHN) into a phase III clinical trial with p53 gene therapy. The goal of this study is to evaluate whether this investigational therapy improves survival in patients. Additionally, the trial is designed to compare the new therapy with methotrexate, a commonly used chemotherapy treatment. The secondary end points include, tumor growth control rate, impact on quality of life and effectiveness of the gene therapy in reducing cancer morbidity when compared with methotrexate. The trial will involve 240 patients at more than 60 institutions in the United States, Canada and Europe. The therapy consists of a normal p53 gene delivered to the tumor using an adenoviral delivery system. Recent research has found that more than 50 percent of tumors in patients with head and neck cancer have a defective p53 gene, which is known to play a role in many types of cancers.



Home ~ Overview ~ Mission ~ Members ~ Clinical Trials ~ Course Info
Research ~ Core Facilities ~ Other Links ~ Contact Us